Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection

PHASE1TerminatedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

June 25, 2021

Primary Completion Date

November 17, 2022

Study Completion Date

November 17, 2022

Conditions
Chronic Hepatitis
Interventions
DRUG

AB-836

Capsules or Tablets

DRUG

Placebo

Capsules of Tablets

DRUG

AB-836

Tablets

DRUG

Placebo

Tablets

DRUG

Nucleos(t)ide Analogue

Tablets

Trial Locations (15)

Unknown

Royal Prince Alfred Hospital, Camperdown

Nepean Hospital, Kingswood

Ottawa Hospital Research Institute, Ottawa

Toronto Liver Center, Toronto

Queen Mary Hospital, Hong Kong

Arensia Exploratory Medicine, Chisinau

New Zealand Clinical Research Auckland, Auckland

Pusan National University Hospital, Busan

Asan Medical Center, Seoul

Hospital For Tropical Diseases, Bangkok

King Chulalongkorn Memorial Hospital, Bangkok

Maharaj Nakorn Chiang Mai Hospital, Chiang Mai

Srinagarind Hospital, Khon Kaen

Naresuan University Hospital, Phitsanulok

Medical Center of Limited Liability Company Arensia Exploratory Medicine, Kyiv

Sponsors
All Listed Sponsors
lead

Arbutus Biopharma Corporation

INDUSTRY

NCT04775797 - Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection | Biotech Hunter | Biotech Hunter